Skip to main content


Schizophrenia Market Size & Share 2030 | Delveinsight In 2017, the total prevalent population of Schizophrenia in the 7MM was 5,616,463. Among 7MM, the EU5 countries occupied 22.47% of the patient pool in 2017. The market size of Schizophrenia in 7MM was USD 6,066.97 million in 2017. The key companies in the Schizophrenia market include Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, Sunovion/PsychoGenics, Acadia Pharmaceuticals, Forum Pharmaceuticals, BioXcel Therapeutics, Avineuro Pharmaceuticals, Alkermes, Avanir Pharmaceuticals/Otsuka Pharma, Takeda, SyneuRx International, Biogen, Cerevel Therapeutics/Pfizer, Concert Pharmaceuticals, Newron Pharmaceuticals, Corcept Therapeutics, Merck, and Celon Pharma. For more details, visit: https://www.delveinsight.com/report-store/schizophrenia-market